Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals IncfiledCriticalAlnylam Pharmaceuticals Inc
Publication of CL2017002646A1publicationCriticalpatent/CL2017002646A1/en
<p>La invención se relaciona con agentes de ARNi, por ejemplo, agentes de ARNi de doble hebra, que se dirigen Contra el gen de Serpina1, y métodos para usar dichos agentes de ARNi para inhibir la expresión de Serpina1 y métodos para tratar a sujetos que tienen una enfermedad asociada a Serpina1 tal como un trastorno de hígado.</p><p> The invention relates to RNAi agents, for example, double-stranded RNAi agents, which are directed against the Serpina1 gene, and methods for using said RNAi agents to inhibit the expression of Serpina1 and methods for treating subjects who have a disease associated with Serpina1 such as a liver disorder. </p>
CL2017002646A2013-05-222017-10-18
Compositions of serni arni1 and their methods of use (divisional application No. 3441-2015).
CL2017002646A1
(en)
COMPOSITIONS OF ARNi AGAINST FACTOR XII (HAGEMAN FACTOR) (F12), CALICREIN B, PLASMATIC (FLETCHER FACTOR) 1 (KLKB1), AND QUININOGEN 1 (KNG1) AND METHODS OF USE OF THE SAME